We are thrilled to announce that Bayer is joining us as a sponsor for the 2024 Pediatric Early Development Symposium (PEDS), hosted by CureSearch. This exciting virtual event, taking place on October 9th and 10th, will delve into the ever-evolving regulatory landscape surrounding pediatric cancer. Attendees can look forward to insightful discussions on how these changes impact the translation of groundbreaking lab discoveries into effective, commercially available treatments for children battling cancer.
Founded in 1863, Bayer has a rich history in healthcare, launching its pharmaceutical division in 1881 and becoming widely recognized for developing Aspirin in 1899. Today, Bayer continues to innovate across various sectors, including pharmaceuticals, consumer health, and crop science. Their dedicated oncology department is focused on transforming cancer research through collaboration and cutting-edge advancements, ultimately striving to improve the lives of cancer patients.
To discover more about Bayer and their commitment to oncology, visit their websites: Bayer and Bayer Oncology.
A heartfelt thank you to Bayer for supporting PEDS as we work tirelessly to ensure that children with cancer not only survive but thrive.To register for 2024 PEDS, visit: curesearch.org/peds2024.
